^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
12/03/2020
Excerpt:
Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…First-line therapy…other recommended regimens...Zanubrutinib (for patients with contraindication to other BTKi)
Source:
Title:
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Excerpt:
Ninety-one patients (82 CLL, 9 SLL) enrolled in the study and received at least one dose of zanubrutinib....Subgroup analysis of ORR revealed results generally consistent with the overall study population, including in subgroups with poor prognostic features (e.g., IGHV unmutated status [82%], del(17p)/TP53 mutation [86%], and refractory disease [83%])...Responses were observed in 19 (86.4%) of 22 patients with either del(17p) or TP53 mutation...
DOI:
10.1186/s13045-020-00884-4
Trial ID:
